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Abstract
Background: Post-herpetic neuralgia (PHN) is the most common complication in herpes zoster (HZ) patients.
Methods: We performed a longitudinal, prospective study in 108 general practices throughout Italy to assess how
many immunocompetent patients aged ≥50 years with newly diagnosed HZ develop HZ-associated pain, its duration
and management over 6-months. HZ-associated pain was assessed by a direct question to the patient and by
self-assessment of the worst pain felt in the previous two weeks on a visual analogue scale (VAS), a score ≥3 was
taken as pain. PHN was defined as pain reported during the study period persisting for ≥3 months. Quality of life
(QoL) was measured using the SF-12 questionnaire.
Results: At enrolment, 370 of the 413 patients (89.6%) reported HZ-associated pain which was still present in 20.6%
and 9.2% of patients after three and six months, respectively, despite many patients receiving recommended anti-viral
therapy. The overall QoL scores were lower than those in healthy Italians of similar age; scores for patients with
HZ-associated pain were lower. The presence of >50 vesicles and VAS score ≥3 at enrolment, and being male
were significantly associated with PHN at three months.
Conclusions: These results suggest that HZ and PHN represent an important burden of disease in the elderly.
There is a need for interventions that can prevent and reduce the burden of HZ to help improve the quality of
life of the elderly. These data may be useful as baseline epidemiology data for the assessment of the impact of
the VZV vaccine in Italy, after its implementation.
Keywords: Post herpetic neuralgia, Herpes zoster, Shingles, Pain, Varicella zoster virus, Vaccine-preventable diseases,
Prospective study, Italy
Background
Varicella zoster virus (VZV) is a herpes virus that infects
nearly all humans in temperate regions resulting in a
highly contagious primary infection of varicella, usually
in childhood [1]. After this infection, the virus remains
latent in sensory ganglia until it is reactivated to cause
herpes zoster (HZ) [2]. In Europe, almost all adults
(>95%) are healthy carriers of VZV following childhood
varicella and are, therefore, at risk of developing HZ [3].
The immune system declines with age (immunosenes-
cence); the decline of VZV-specific T-cell-mediated im-
munity is thought to be involved in this reactivation [4].
The incidence and severity (number of vesicles, and pain
intensity and duration) of HZ increase with age, but it is
difficult to predict who will develop HZ [5,6]. Although
patients with treatment- or disease-associated immuno-
suppression are at higher risk for HZ, 90% of patients
with HZ are immunocompetent. Other risk factors include
sex, ethnicity, genetic susceptibility, familial history of HZ,
mechanical trauma, psychological stress, depression and
diabetes [7-9].
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Herpes zoster is characterized by a, usually painful,
unilateral vesicular rash, generally limited to a single
dermatome, corresponding to the sensory ganglion
from which the latent VZV was reactivated [10]. The
most frequent localization (>50%) is thoracic, followed
by cranial, including the ophthalmic division of the tri-
geminal nerve; the incidence of this latter localization
increases with age [11].
Pain may occur during three distinct phases of the
disease:
prodromal pain: often occurs prior to rash onset;
acute pain or neuritis: begins with the rash and usually
disappears within 2 to 4 weeks;
chronic pain i.e. post-herpetic neuralgia (PHN): most
commonly defined as pain occurring or persisting for
≥3 months after rash onset.
HZ-associated pain is debilitating and often has a
substantial, negative impact on patients’ normal life and
health, particularly among the elderly whose activities and
basic tasks of daily living can be impaired and anxiety and
depression can occur [12,13]. In addition, when PHN
occurs, pain management is difficult and patients suffer
from important side effects [14]. Treatment with anti-
viral agents within 72 hours of rash onset for seven days
is recommended in some patient groups to accelerate
rash healing and to limit the severity and duration of
pain [15]. However, observational studies in France,
Italy, the Netherlands and the UK and a meta-analysis
gave heterogeneous results [16-20].
The annual HZ incidence is similar throughout
Europe, increasing with age from around 1–4/1 000 in
adults aged <50 years to about 7–8/1 000 in those ≥50 years,
up to 10/1 000 at >80 years [21]. After the introduc-
tion of antivirals drugs, about 10% to 30% of patients
aged ≥50 years with HZ develop PHN in Europe [22].
Most studies estimating the percentage of patients with
HZ who develop PHN are retrospective. In addition, there
is no consensus for the definition of PHN making compar-
isons between studies difficult [22].
In Italy, there are insufficient data on the burden of
HZ and PHN because there is no HZ-specific national
surveillance system. In one nationwide study the annual
incidence of general practitioner (GP) visits for HZ was
4.1/1 000 persons aged ≥15 years; 19.6% presented with
PHN and 26.1% presented ≥1 complications [23]. One
study in 2004 in the Piedmont region reported an overall
HZ incidence rate of 1.59/1 000 inhabitants and a
hospitalization incidence rate of 0.12/1 000 [24]. In an-
other study that analysed data from four regions in Italy,
the HZ incidence in adults aged ≥50 years was 6.6/1
000, and 9.4% and 7.2% of the patients had PHN at
1 month and 3 month, respectively [25]. Another study
that analysed data from 1999 to 2005 reported a mean
annual number of 4 503 HZ hospitalisations and 543 day-
hospitalisations; 62% of patients were >65 years [26].
In the perspective of a VZV vaccine to prevent and
reduce the severity of HZ becoming available in Europe,
it was decided to obtain baseline data on the occurrence
of PHN in a multicenter, longitudinal, prospective, ob-
servational study involving general practitioners (GPs)
throughout Italy, the HER.O.E.S. Study – HERpes zoster
Outcome: Epidemiological Study. The primary objective
was to assess the percentage of patients with HZ that
have HZ-associated chronic pain and its duration.
Methods
This study was conducted in compliance with the
Declaration of Helsinki (Seoul revision; 2008), Good
Epidemiological Practice Guidelines and Italian national
regulations [27,28]. The protocol and study documenta-
tion were approved by Ethics Committee for each local
health unit (See Table 1).
Study objectives
The co-primary objectives of the six-month study were:
to assess the percentage of patients with HZ who
developed HZ-associated chronic pain and how long
the pain lasted.
to collect disease management data from diagnosis to
resolution of the acute symptoms, and data on the
management of HZ-related pain.
The secondary objectives were to assess quality of life
(QoL) in the patients with HZ/PHN using the SF-12
instrument and to assess HZ-related pain intensity using a
visual analogue scale (VAS). We also recorded the pres-
ence of clinical variables that have been identified as risk
factors for HZ and assessed the patients’ care pathway and
their disease progression during the study period.
Study design
Patients aged >50 years old with a new clinical diagnosis
of HZ, who were immunocompetent and who signed
an informed consent form were enrolled in the study.
Each patient was expected to attend four visits at 0, 1
(± 15 days), 3 (± 21 days) and 6 (± 30 days) months.
Patients could be excluded from the analysis for one
visit for non-respect of the time window, but included
in the analysis for a subsequent visit, if it occurred
within the time window.
At the initial visit (V0), descriptive information was
collected: socio demographic data, clinical description,
medical history. The patients were asked if they had HZ-
associated pain at the visit and their quality of life was
assessed using the physical component summary (PCS-12)
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Table 1 List of local ethics committees that approved the protocol and study documentation
Local health unit IRB/IEC name IRB/IEC address
Alessandria Comitato Etico Via Venezia, 16
Azienda Osped. SS. Antonio e Biagio e Cesare Arrigo 15100 Alessandria
Asolo Comitato Etico Borgo Cavalli, 42
Azienda ULSS N. 9 di 31100 Treviso
Treviso
Asti Comitato Etico Via Venezia, 16
Azienda Ospedaliera SS. Antonio e Biagio 15100 Alessandria
e Cesare Arrigo
Bologna Comitato Etico Via Gramsci, 12
Azienda USL di Bologna 40121 Bologna
Dipartimento Farmaceutico
Brindisi COMITATO ETICO Via Napoli, 8
ASL n. 1 di BRINDISI 72100 Brindisi
Bussolengo Comitato etico Via Salvo D’Acquisto, 7
Provincia di Verona Azienda ULSS 20 di Verona c/o Dipartimento 37122 Verona
Farmaceutico
Carbonia Comitato Etico Via Dalmazia, 83
ASL di Carbonia 09013 Carbonia
Catanzaro Comitato Etico Via Vinicio Cortese, 25
Azienda Sanitaria 88100 Catanzaro
Provinciale di Catanzaro
Ferrara Comitato Etico Corso Giovecca, 203
c/o Ufficio Ricerche e Innovazioni 44100 Ferrara
Azienda Ospedaliero, Universitaria di Ferrara
Genova Comitato Etico Via Bertani, 4
Asl 3 Genovese 16125 Genova
Grosseto Comitato Etico Via Genova, 6/D
c/o U.O. Farmaceutica Territoriale - Azienda USL n. 9 di Grosseto 58100 Grosseto
Lecce Comitato Etico Via Miglietta, 5
ASL di Lecce 73100 Lecce
Milano Comitato Etico ASL Città di Milano Via Statuto, 5
c/o Servizio Farmaceutico 20121 Milano
Napoli/5 Comitato Etico Piazza San Giovanni
ASL Napoli 3 Sud 80031 Brusciano (NA)
Pavia Comitato Etico Via Indipendenza, 3
Asl Provincia di Pavia 27100 Pavia
Pescara Comitato Etico Via Fonte Romana, 8
ASL di Pescara 65100 Pescara
Ragusa Comitato Etico Piazza Igea, 2
Azienda USL 7 di Ragusa 97100 Ragusa
Roma/C Comitato Etico Piazzale Umanesimo, 10
c/o Direzione Amministrativa Ospedale Sant’Eugenio 00144 Roma
Roma/H Comitato Etico Borgo Garibaldi, 12
ASL Roma H di Albano 00041 Albano Laziale (RM)
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and the mental component summary (MCS-12) scores
from the SF-12 questionnaire. The scores ranged from 0
(lowest level of health) to 100 (highest level of health)
[29]. A score of <50 indicates a below-average health sta-
tus. The level of pain was assessed using a visual analogue
scale (VAS) for the worst pain felt during the previous two
weeks, with scores ranging from 0 (‘no pain’) to 10 (‘worst
pain imaginable’). A VAS score of ≥3 was considered to be
correlated with pain interfering with activities of daily
living [30]. At each follow-up visit the presence of
HZ-associated pain, the level of pain using the VAS
and quality of life (QoL) scales were assessed. In
addition, data on the clinical evolution and the health
care resources used were collected.
The presence of allodynia, itching, paresthesia and
malaise were all assessed by the physicians during the
clinical examination at corresponding study visit. Data
were collected using an electronic case report form (eCRF)
which enabled a real-time quality control of the data at
entry. In addition, a clinical research assistant telephoned
the GPs monthly and also performed ad hoc monitoring
visits during the study.
Assessment of HZ-associated pain
In HEROES, PHN (primary outcome) was defined as pain
that persisted for more than three months after rash onset
assessed by the patient replying ‘yes’ at a study visit when
asked by the GP about the presence of HZ-associated
pain. This assessment mode was chosen to be pragmatic,
since physicians do not use tools to measure pain system-
atically. For the secondary outcome, HZ-associated pain
was assessed with a score ≥3 on the VAS, reflecting the
worst pain the patient had felt during the two-weeks prior
to the visit.
Sample size calculation
Based on information obtained from a questionnaire
survey conducted on 317 GPs throughout Italy in 2008
that collected data on the number of patients with HZ
they treated annually and how many had PHN, and
other published data, [31-33] we assumed that between
15% and 40% of patients with HZ would have HZ-
associated pain. Thus, with a threshold of p = 0.05 and
a pain incidence of 40%, it was estimated that we
needed to enrol 400 patients to guarantee a precision
of ±4.8%. We decided to enrol 500 patients to allow for
20% erroneously-enrolled patients.
Statistical analyses
The descriptive analyses were performed with SAS
(Statistical Analysis System), V9.2. The recorded or derived
variables were summarized as frequencies (absolute or rela-
tive) or means or medians with their associated distribution
(number of observations, mean, standard deviation, me-
dian, minimum, maximum). For all clinically-relevant
variables, 95% confidence intervals (CIs) were calculated.
Analyses were stratified on gender, age group (50–59,
60–69 and ≥70), and presence of pain at the respective
visit.
Variables present at the initial visit associated (p = 0.25)
with PHN at 3-months in univariate analyses were in-
cluded in a multivariate regression model to identify PHN
predictive factors (p ≤ 0.05). The fit of the final model was
assessed using the Hosmer and Lemeshow goodness-of-fit
Table 1 List of local ethics committees that approved the protocol and study documentation (Continued)
Laziale
Teramo Comitato Etico Circonvallazione Ragusa, 1
c/o Servizio Farmaceutico Territoriale - ASL 106 di Teramo 64100 Teramo
Torino/1 Segreteria Tecnico-Scientifica del Comitato Etico Corso Svizzera 185 BIS
ASL TO 2 10149 Torino
Treviso Comitato Etico Borgo Cavalli, 42
Azienda ULSS N. 9 di 31100 Treviso
Treviso
Varese Segreteria del Comitato Etico c/o Direzione Sanitaria ASL della Via Ottorini Rossi, 9
Provincia di Varese 21100 Varese
Verona Comitato Etico Via Salvo D’Acquisto, 7
Provincia di Verona Azienda ULSS 20 di Verona c/o Dipartimento Farmaceutico 37122 Verona
Vibo Valentia Comitato Etico Via Dante Alighieri, Palazzo
ASL 8 di Vibo Valentia ex
Inam - 89900 Vibo Valentia
Note: sites of Genova, Pavia, Alessandria, Asolo were not activated and did not enrol patients.
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test. The estimated β coefficients and the corresponding
95% CIs were calculated. Odds ratios and the correspond-
ing 95% CIs were also calculated.
Results
Patient population
A total of 108 of the 147 GPs who accepted to partici-
pate in the study included at least one patient. These
108 GPs were from 21 local health units localized in 12
Italian regions. Their regional distribution was similar to
the national distribution (data not shown). They enrolled
435 patients with a new diagnosis of HZ from 27 March
2009 to 5 July 2010 of whom 413 were included in the
study (Figure 1).The majority of the GPs (72.2%) respected
the time windows for all their patients’ follow-up visits.
The patients were aged 67.9 ± 10.7 years old and 64.2%
were women (Table 2). Almost half (46.7%) of the study
population were aged ≥70 years. The majority (81.4%)
lived with their family; about 25% were working. Most
patients (90.3%) had been followed by their GP for >5 years
with a mean of 8.2 visits during the previous 12 months.
More than 60% of the patients presented ≥1 chronic con-
dition (diabetes, chronic cardiovascular disease or chronic
respiratory diseases); the percentage increased with age.
Clinical characteristics and treatment of HZ
The mean delay from HZ prodrome and rash onset to
consultation was 4.5 days and 3 days, respectively. This
delay was longer in older patients; delay since prodrome:
3.7 days for those aged 50–59; 4.3 days for those aged
60–69 and 5.1 days for those aged ≥70 and since rash
onset: 2.3 days for those aged 50–59; 2.7 days for those
aged 60–69 and 3.2 for those aged ≥70. All patients
(100%) presented with a rash and 77% had <50 vesicles.
The rash was mainly localized in the thoracic dermatome
area (59.1%) followed by cervical (15.0%), lumbar (13.8%),
cranial (12.6%) and sacral segment (11.1%) dermatome
areas, respectively (Table 2).
Among the patients presenting with pain at the initial
visit, 59.7% had allodynia, 74.3% itching and 58.9% pares-
thesiae (Table 3). Many patients who reported pain during
the study follow-up visits still had allodynia (49.2%, 56.2%
Enrolled
N= 435
Data entered in eCRF 
N= 430
Completed at least 6-month 
visit N=385
No data entered in eCRF 
N= 5
•2 GPs enrolled 4 patients and 
then withdrew from study
•1 GP lost all patient data
Excluded from analysis
N= 17
• 13: aged <50 years
• 1: concomitant disease
• 1: error of diagnosis
• 2: not specified
Included in analysis 
population
N= 413
Completed study 
(attended at least 6-
month visit) N= 382
Did not complete 
follow-up
N= 31
• 4: protocol deviation
• 3: lost-to-follow-up
• 1: withdrew consent
• 23: other reason
Figure 1 Disposition of included patients.
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and 52.9% at the 1-month, 3-month and 6-month visits,
respectively) whereas there was a decrease in the percent-
age of patients with paresthesiae and itching.
Most of the patients (91.5%) received an oral antiviral
(acyclovir: n = 149; brivudin: n = 103; valacyclovir: n = 86;
famciclovir: n = 42) for a median duration of 6.0 days.
Oral antiviral treatment was initiated a median of two
days after rash onset (mean = 3.4 days); 70% of the pa-
tients initiated oral antiviral treatment within three days
after rash onset. Topical antiviral treatment was adminis-
tered to 9.4% of patients (acyclovir: n = 37; tromantadine
hydrochloride: n = 2).
Only 23% of the patients received pain therapy for a
median duration of 12.5 days (mean = 3 days); analgesics
(codeine-paracetamol, oxycodone, paracetamol, trama-
dol, tramadol-paracetamol) (n = 48), nonsteroidal anti-
inflammatory drugs (NSAID)s (n = 36), anti-epileptics
(n = 29) or psycho-analeptics (n = 12).
Among the 104 patients who worked at the initial visit,
36 took sick-leave due to their HZ episode for: 1 to
5 days (53%); 6 to 10 (33%); and more than 10 days
(14%). At the 1-month visit, 33 patients reported that
they had taken sick-leave, 2 at the 3-month visit and 1 at
the 6-month visit.
About 12% of the patients (n = 52) consulted ≥1 special-
ist during the study (mainly a dermatologist, neurologist
or ophthalmologist). None of the patients were hospita-
lised due to HZ.
Herpes zoster-associated pain
Overall, 370/413 (89.6% [86.2-92.3]) patients reported
HZ-associated pain at the initial visit with a mean score
of 5.8 ± 2.4 (Table 3). Among the 353 patients who com-
pleted the three-month visit 73 (20.6% [16.5-25.2]) still
reported pain, satisfying our definition for PHN; the per-
centage increased with age (14.3% of those aged 50–59
Table 2 Baseline characteristics of included subjects
Number of patients (%) 50-59 60-69 ≥70 Males Females Total
107 (25.9) 113 (27.4) 193 (46.7) 148 (35.8) 265 (64.2) 413 (100)
Age, years, mean ± SD 54.5 ± 2.8 64.4 ± 2.9 77.4 ± 6.2 68.3 ± 11.0 67.7 ± 10.6 67.9 ± 10.7
Gender, %, M/F 33.6/66.4 33.6/66.4 38.3/61.7 - - 35.8/64.2
Employment status n (%)
Worker 79 (73.8) 23 (20.4) 2 (1.0) 46 (31.1) 58 (21.9) 104 (25.2)
Retired 11 (10.8) 76 (67.3) 184 (95.3) 102 (68.9) 169 (63.8) 271 (65.6)
Other 17 (15.9) 14 (12.4) 7 (3.6) - 38 (14.3) 38 (9.2)
Medical history, n (%)
Diabetes 14 (13.1) 19 (16.8) 39 (20.2) 25 (16.9) 47 (17.7) 72 (17.4)
Type 1 3 (2.8) 0 3 (1.6) 4 (2.7) 2 (0.8) 6 (1.5)
Type 2 11 (10.3) 19 (16.8) 36 (18.7) 21 (12.2) 45 (17.0) 66 (16.0)
Chronic cardiovascular diseases 26 (24.3) 61 (54.0) 139 (72.0) 84 (56.8) 142 (53.6) 226 (54.7)
Chronic respiratory diseases 6 (5.6) 13 (11.5) 33 (17.1) 27 (18.2) 25 (9.4) 52 (12.6)
Other relevant diseases 29 (27.1) 51 (45.1) 100 (51.8) 60 (40.5) 120 (45.3) 180 (43.6)
Rash localization n (%)
Cranial 16 (15.0) 14(12.4) 22 (11.4) 15 (10.1) 37 (14.0) 52 (12.6)
Cervical 19 (17.8) 23 (20.35) 20 (10.4) 19 (12.8) 43 (16.2) 62 (15.01)
Thoracic 61 (57.0) 63 (55.8) 120 (62.2) 92 (62.2) 152 (57.4) 244 (59.1)
Lumbar 15 (14.0) 12 (10.62) 30 (15.5) 22 (14.9) 35 (13.2) 57 (13.8)
Sacral 12 (11.2) 11 (9.73) 23 (11.9) 17 (11.5) 29 (10.9) 46 (11.1)
Number of vesicles, n (%)
None 5 (4.7) 4 (3.5) 6 (3.1) 6 (4.1) 9 (3.4) 15 (3.6)
Less than 50 83 (77.6) 88 (77.9) 147 (76.2) 112 (75.7) 206 (77.7) 318 (77.0)
More than 50 18 (16.8) 21 (18.6) 40 (20.7) 30 (20.3) 49 (18.5) 79 (19.1)
SF-12 (mean, SD)
Physical Health Score (PCS-12) 42.7 ± 7.6 41.4 ± 8.0 37.6 ± 9.2 41.5 ± 8.4 39.4 ± 8.8 40.1 ± 8.7
Mental Health Score (MCS-12) 41.9 ± 10.8 42.6 ± 10.0 41.0 ± 10.9 45.2 ± 10,0 39.8 ± 10.4 41.7 ± 10.6
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years, 20.2% of those aged 60–69 years and 24.5% of
those aged ≥70 years) (Figure 2A). PHN was still
present in 34 of the 368 patients at the six-month visit
(9.2% [6.5-12.7]). The prevalence of pain at the month
3 and 6 visits was higher among patients who reported
pain at the one-month visit (Figure 3). There was a
non-statistically significant trend for more men than
women to report pain at the one- and three-month
visits (all p values >0.05).
The mean VAS score for patients who reported pain at
each visit decreased from 5.8 (median 6) at enrolment to
3.7 (median 3) at the six-month visit. The percentage of
patients with a VAS score ≥3 was 81.7% [77.6% - 85.4%]
at the initial visit; 49.7% [44.5% - 54.9%] at the 1-month
visit; 22.4% [18.1% - 27.2%] at the 3-month visit and
15.2% [12.0% - 20.0%] at the 6-month visit (Figure 2B).
Predictive factors for persistent HZ-associated pain
The results from the univariate analyses showed that the
presence at the initial visit of >50 vesicles, allodynia,
a VAS score ≥3, the PCS-12 score, the presence of
diabetes or chronic cardiovascular disease or respira-
tory disease, age, a rash localized on the lumbar
dermatome, being male and the MCS-12 score were
potential predictive factors for the persistence of pain
at three months (PHN). Multivariate analysis, includ-
ing these variables, showed that the presence of >50
vesicles (OR = 2.595 [1.267-5.314]), a VAS score ≥3
(OR = 4.599 [1.181-17.907]) and being male (OR = 2.017
[1.006-4.042]) were significantly associated with PHN
(p < 0.05) (Table 4).
Quality of life assessment
At the initial visit, the patients’ mean SF-12 scores were
below the mean value of 50 (PCS-12 score = 40.1 ± 8.7,
MCS-12 score = 41.7 ± 10.6 – Table 2). Both scores were
lower in women and in older patients, particularly the
PCS-12 score; patients without pain present at the visit
had higher scores than those with pain. The mean PCS-12
and MCS scores in the study were lower than those in the
healthy Italian population (Table 2) [34]. During the study,
the PCS-12 and MCS-12 scores in patients presenting
with pain at the respective visit did not vary, except for a
small decrease in the MCS-12 score (Table 3).
Discussion
The results from this prospective study, performed in a
large network of GPs in Italy, show that patients aged
≥50 years report that HZ is painful, it has a negative
impact on their QoL, working patients need to take sick
leave and increasing age is a risk factor for severity. The
incidence of PHN was high (20.6% at three-months and
9.2% at 6-months), although the majority of patients re-
ceived antiviral treatment.
All the patients included had a rash even if the pres-
ence of rash was not an inclusion criterion, suggesting
that the GPs diagnosed HZ based on the presence of the
typical rash. We cannot exclude erroneous diagnosis
since there was no laboratory confirmation. In the pivotal
HZ vaccine clinical trial in adults, 5–6% of the clinical
diagnoses were not confirmed in the laboratory [35]. Simi-
larly, a prospective study of HZ diagnoses by GPs found
17% of diagnoses to be incorrect [36].
Table 3 Assessment and characteristics of the HZ-associated pain and quality of life scores at each study visit
Visit
Enrolment 1 month 3 months 6 months
Number of patients who completed the visit 413 390 353 368
Patients reporting pain at the respective visit
Number of patients 370 193 73 34
Mean VAS score for patients reporting pain ± SD 5.8 ± 2.4 4.4 ± 2.3 3.7 ± 2.0 3.7 ± 2.3
Main characteristics of HZ-associated pain (%)
Allodynia 59.7 49.2 56.2 52.9
Itching 74.3 27.5 21.9 17.7
Paresthesia 58.9 49.7 52.1 38.2
Malaise 20.8 14.0 13.7 8.8
Quality of life score (SF12)
Mean PCS-12 score ± SD 39.2 ± 8.4 37.7 ± 8.3 40.1 ± 8.4 39.0 ± 9.3
Mean MCS-12 score ± SD 41.6 ± 10.4 39.3 ± 10.4 39.6 ± 9.8 39.4 ± 10.6
Patients with a VAS score ≥3 at the respective visit
Number of patients 308 175 71 50
Mean VAS score among these patients 6.4 ± 1.9 5.2 ± 1.9 4.9 ± 1.8 5.4 ± 2.1
Bricout et al. BMC Infectious Diseases 2014, 14:637 Page 7 of 11
http://www.biomedcentral.com/1471-2334/14/637
In HEROES, the patients enrolled do not seem to have
suffered from severe disease as none were hospitalised.
In Italy, the HZ hospitalization rate has been reported to
be 5.6 per 100,000 patients and 10.3 per 100,000 for
those with PHN [25]. The study was designed to have
sufficient power to estimate the percentage of patients
with HZ-associated pain, but was insufficient to detect
HZ hospitalization. It is possible that patients with more
severe disease may have consulted a specialist or were
hospitalized directly. In addition, the low rate of consul-
tations with specialists (12.3% during the six-month
study) and the delay of about three days between rash
onset and the GP visit suggest that the patients included
in this study were suffering from non- severe to
moderately-severe disease.
We observed a higher incidence of HZ-associated pain
than that observed in the placebo group of the pivotal
study (12% for PHN 3 months); however, the percentage
of men was higher in the pivotal study and the subjects
were older (≥60 years) so the age distribution was different
[35]. In a French study, 11.6% of patients with HZ suffered
from HZ-associated pain at 3-months, as declared by the
patients whereas in a UK study there were about 27% of
patients who suffered from PHN [16,32]. These differ-
ences could be due to different access to healthcare
and pain management or the method used to assess
the HZ-associated pain. This last point is highlighted
by the slightly different estimates for HZ-associated
pain for the primary and secondary outcomes we ob-
served in our study. Additionally, the VAS score was
missing for 10.2% and 13.6% of patients at the 3- and
6-month visits, respectively; we cannot exclude that
patients who suffered more from pain were more likely
to complete the VAS score.
The percentage of patients with PHN reported in
retrospective database studies ranged from 6.9% to 32%
[21,25,33,37-39]. Retrospective studies using International
Classification of Disease (ICD) codes to extract data from
databases do not always provide a reliable estimate of HZ
and PHN incidences because of possible miscoding and
under-coding. Additionally, the absence of a specific ICD
code for PHN makes database extraction less reliable for
this endpoint. The prospective design of our study, includ-
ing three follow-up visits, enabled a better diagnosis of
PHN than retrospective studies. Nevertheless, even if the
actual estimates were different, the studies also generally
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reported an age-related increase in the percentage of pa-
tients with HZ-associated pain. The percentage of patients
with PHN observed in HEROES was lower than the 40%
assumed for the sample size estimation. Although we
recruited fewer than the original target of 500 patients, we
had data for the planned 400 patients needed to estimate
the percentages of patients with PHN at 3 and 6 months
with good precision. PHN can last for several months to
several years but in this study we followed the patients for
six months. This may have led to an underestimation of
the true clinical burden of PHN. In this study, general
practitioners recruited the participants. In Italy patients
need to be referred for specialist care by their general
practitioner, and even when they use private healthcare to
consult a specialist directly, they have to report to their
general practitioner for reimbursement of prescriptions
via the national health system. Hence are results are likely
to be generalizable in healthcare systems requiring referral
for specialist appointments.
The presence of >50 vesicles, a VAS score ≥3 and be-
ing male were identified as variables that were associated
with PHN at three months. The first two variables have
been reported previously to be associated with a higher
risk of developing PHN at three months suggesting that
PHN is probably linked to more severe acute episodes of
HZ [16]. However, other studies have either not reported
any gender differences or have reported an increased
risk in women, unlike our study. This may be due to dif-
ferences in study methodology or, perhaps, in our study,
women underestimated the level of their pain. It is also
conceivable that there are more women in the older-age
groups, so that there is confounding with age [40].
Most of the patients (91.5%) in HEROES received anti-
virals as recommended, which is similar to that reported
in other studies [15,16,22]. In contrast, only 23% of our
patients were reported as receiving pain therapy. This
could be due to the low disease severity or because in
Italy the most frequent pain therapies, i.e. paracetamol
and NSAIDs are available without prescription and were,
therefore, not reported by the physicians.
With the predicted ageing of the European population
in the coming decades, the number of people affected by
HZ and its related complications, including PHN, can
Table 4 Predictive factors for persistentHZ-associated pain – results from multivariate regression
Explanatory variable Level of explanatory variable P value OR estimates 95% CI
More than 50 vesicles Yes vs no 0.0091 2.595 1.267-5.314
VAS score ≥3 at V0 Yes vs no 0.0278 4.599 1.181-17.907
Gender Male vs female 0.0481 2.017 1.006-4.042
Presence of allodynia Yes vs no 0.1039 1.812 0.005-3.710
MCS-12 score Continuous variable 0.2858 0.982 0.951-1.015
Age Continuous variable 0.5420 1.011 0.977-1.046
Associated diseases* Yes vs no 0.6162 1.226 0.553-2.719
PCS-12 score Continuous variable 0.6853 0.992 0.952-1.033
Rash area (lumbar dermatome) Yes vs no 0.8261 1.111 0.435-2.836
*Presence of diabetes, chronic cardiovascular disease or chronic respiratory diseases.
Hosmer and Lemeshow goodness-of-fit test: p = 0.4098.
MCS-12 score: SF12 mental component summary score; PCS-12 score: SF12 physical component summary score.
The variables that were significantly predictive of pain present at 3 months were having more than 50 vesicles at V0, VAS score ≥3 at V0 and being male.
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also be expected to increase [41]. Preventive strategies,
including vaccines, are thought to play an important role
in the promotion of healthy ageing. Immunosenescence
is reported to increase the risk of developing HZ due to
an impaired T -cell-mediated immunity. In the Shingles
Prevention Study, a live-attenuated Oka/Merck strain
VZV vaccine was shown to reduce the incidences of HZ
and PHN significantly, compared with placebo [35]. This
vaccine is indicated in the EU for adults aged ≥50 years;
in 2013, the UK started a shingles vaccination program
targeting those aged between 70 and 79 years.
Conclusions
These data suggest that there is an important burden of
disease in the elderly due to HZ. There is a need for in-
terventions that can prevent and reduce the burden of
HZ to help improve the quality of life of the elderly.
These data may be useful as baseline epidemiology data
for the assessment of the impact of the VZV vaccine in
Italy, after its implementation.
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